Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

EMA To Share Generics Data To Speed Access, But Pitfalls Remain

This article was originally published in The Pink Sheet Daily

Executive Summary

The EMA has announced that it is ready to share information on generic marketing authorizations with other regulators, which should speed market access, but industry remains concerned about patent linkage and discriminatory regulatory standards.

You may also be interested in...



EU/U.S. Trade Pact Talks May Stumble Over Drug Regulation, Affordability

The EU Parliament’s health committee has highlighted regulatory pitfalls within TTIP, while civil society elements decry its lack of transparency and potential impact on health care affordability.

European Commission May Pursue More Antitrust Actions Against Pharma

The EC is scrutinizing pharma practices that may delay generic entry and advocating changes in the patent system.

MHRA’s Beneficial EU Relationship And Profitable Synergies With NICE: An Interview With Michael Rawlins

In December, Michael Rawlins was appointed head of the U.K.’s Medicines and Healthcare products Regulatory Agency. He recognizes the MHRA’s mutually beneficial relationship with European counterparts and is looking to safeguard synergies with other national regulatory bodies and NICE.

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS077789

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel